Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer - a Pilot and Biomarker Study

Trial Profile

Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer - a Pilot and Biomarker Study

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Enoblituzumab (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 22 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 10 Jun 2017 Biomarkers information updated
    • 13 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top